Preparation of gelatin nanoparticles with EGFR selection ability via biotinylated-EGF conjugation for lung cancer targeting

Biomedical Engineering - Applications, Basis and Communications

Volumn 20, Issue 3, 2008, Pages 161-169

  Tseng, Ching Li ^a   Lin, Feng Huei ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Avidin biotin; Cancer; EGF; Gelatin; Nanoparticles

Indexed keywords

BINS; BIOLOGICAL ORGANS; CELLS; CYTOLOGY; DISEASES; EFFICIENCY; MOLECULAR BIOLOGY; SURFACE PLASMON RESONANCE;

ADENOCARCINOMA CELLS; AVIDIN-BIOTIN; CANCER; FLOW CYTOMETRY ASSAYS; GELATIN; GELATIN NANOPARTICLES; PARTICLE CHARACTERIZATION; RECEPTOR-MEDIATED ENDOCYTOSIS;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; GELATIN; LIGAND; NANOPARTICLE;

ARTICLE; ATOMIC FORCE MICROSCOPY; BIOTINYLATION; CANCER DIAGNOSIS; CELL CULTURE; CONJUGATION; CONTROLLED STUDY; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; OSTEOSARCOMA CELL; PARTICLE SIZE; PROTEIN INTERACTION; PROTEIN MODIFICATION; SURFACE PLASMON RESONANCE; SURFACE PROPERTY;

EID: 56549129583     PISSN: 10162372     EISSN: None     Source Type: Journal    
DOI: 10.4015/S1016237208000714     Document Type: Article

References (27)

1. Kerr KM, Pulmonary preinvasive neoplasia, J Clin Pathol 54:257-271, 2001.
2. Mitra S, Gaur U, Ghosh PC, Maitra AN, Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier, J Control Release 74:317-323, 2001.
3. He X, Lin X, Wang K, Chen L, Wu P, Yuan Y et al., Biocompatible core-shell nanoparticles for biomedicine, in Nalwa HS (ed.) Encyclopedia of Nanoscience and Nanotechnology, Steveson Ranch, American Scientific Publishers, pp. 235-253, 2004.
4. Sledge Jr. GW, Miller KD, Exploiting the hallmarks of cancer: The future conquest of breast cancer, Eur J Cancer 39:1668-1675, 2003.
5. Kullberg EB, Bergstrand N, Carlsson J, Edwards K, Johnsson M, Sjoerberg S et al., Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents, Bioconjugate Chem 13:737-743, 2002.
6. Rusch V, Klimstra D, Venkatraman E, Pisters PWT, Langenfeid J, Dmitrovsky E, Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression, Clin Cancer Res 3:515-522, 1997.
7. Vandervoort J, Ludwig A, Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use, Eur J Pharm Biopharm 57:251-261, 2004.
8. Green NM, Avidin, Biochem J 89:585-591, 1963.
9. Hermanson GT, Bioconjugate Techniques, Academic Press, San Diego, p. 465, 1996.
10. Coester CJ, Langer K, Briesen HV, Kreuter J, Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake, J Microencapsul 17:187-193, 2000.
11. Weber C, Reiss S, Langer K, Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups, Int J Pharm 211:67-78, 2000.
12. Young S, Wong M, Tabata Y, Mikos AG, Gelatin as a delivery vehicle for the controlled release of bioactive molecules, J Control Release 109:256-274, 2005.
13. Leo E, Vandelli MA, Cameroni R, Flavio F, Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: Involvement of the drug in the cross-linking, Int J Pharm 155:75-82, 1997.
14. Truong-Le VL, Walsh SM, Schweibert E, Mao H-Q, Guggino WB, August JT et al., Gene transfer by DNA-gelatin nanospheres, Arch Biochem Biophys 361(1):47-56, 1999.
15. Morimoto K, Katsumata H, Yabuta T, Iwanaga K, Kakemi M, Tabata Y et al., Gelatin microspheres as a pulmonary delivery system: Evaluation of salmon calcitonin absorption, J Pharm Pharmacol 52:611-617, 2000.
16. Brannon-Peppas L, Blanchette JO, Nanoparticle and targeted systems for cancer therapy, Adv Drug Deliv Rev 56:1649-1659, 2004.
17. Jain RK, Delivery of molecular and cellular medicine to solid tumors, Adv Drug Deliv Rev 46:149-168, 2001.
18. Jain RK, Normalizing tumor vasculature with antiangiogenic therapy: A new paradigm for combination therapy, Nat Med 7:987-989, 2001.
19. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Shalaby MR et al., Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis, Biochim Biophys Acta 1591:109-118, 2002.
20. Fan Z, Lu Y, Wu X, Mendelsohn J, Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells, J Biol Chem 269:27595-27602, 1994.
21. Weyergang A, Selbo PK, Berg K, Photochemically stimulated drug delivery increases the cytotoxicity and specificity of EGF-saporin, J Control Release 111:165-173, 2006.
22. Klenkler BJ, Griffith M, Becerril C, West-Mays JA, Sheardown H, EGF-grafted PDMS surfaces in artificial cornea applications, Biomaterials 26:7286-7296, 2005.
23. Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K, Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells, J Drug Target 12(7):461-471, 2004.
24. Maione P, Rossi A, Airoma G, Ferrara C, Castaldo V, Gridelli C, The role of targeted therapy in non-small cell lung cancer, Crit Rev Oncol Hematol 51:29-44, 2004.
25. Lee H, Kim TH, Park TG, A receptor-mediated gene delivery system using streptavidin and biotin-derivatized, pegylated epidermal growth factor, J Control Release 83:109-119, 2002.
26. Krupp MN, Connolly DT, Lane MD, Synthesis, turnover and down-regulation of epidermal growth factor receptors in human A431 epidermal carcinoma cells and skin fibroblasts, J Biol Chem 257:11489-11496, 1982.
27. Kirpotin DPJ, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D, Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cells in vitro, Biochem 36:66-75, 1997.